Core Laboratories 과거 순이익 실적
과거 기준 점검 3/6
Core Laboratories은 연평균 8.7%의 비율로 수입이 증가해 온 반면, Energy Services 산업은 수입이 44.6% 증가했습니다. 매출은 연평균 3.2%의 비율로 증가했습니다. Core Laboratories의 자기자본이익률은 10.7%이고 순이익률은 5.5%입니다.
핵심 정보
8.66%
순이익 성장률
8.08%
주당순이익(EPS) 성장률
| Energy Services 산업 성장률 | 23.71% |
| 매출 성장률 | 3.16% |
| 자기자본이익률 | 10.75% |
| 순이익률 | 5.53% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • May 23
CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E
Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).
내러티브 업데이트 • Apr 28
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).내러티브 업데이트 • Apr 14
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Seeking Alpha • Mar 26
Core Laboratories: Profit Margins Are Too Small To Get Excited About
Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking Alpha내러티브 업데이트 • Jan 26
CLB: Fair Value View Will Rely On Stable Margins And P/E Assumptions
Analysts held their price target on Core Laboratories steady at US$18.00, citing only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their overall view of the company. Valuation Changes Fair Value: Held steady at US$18.00, indicating no change in the core valuation output.내러티브 업데이트 • Jan 11
CLB: Fair Value View Will Rely On Stabilizing Margins And EPS
Analysts kept their Core Laboratories fair value estimate around $18.00. The updated price target mainly reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E rather than a major shift in their view of the stock.내러티브 업데이트 • Dec 14
CLB: Future Earnings And Margins Are Expected To Gradually Stabilize
Analysts have modestly reduced their price target on Core Laboratories by 1 dollar to 18 dollars. This reflects a slightly lower fair value despite improved expectations for revenue growth, profit margin, and a less demanding future price to earnings multiple.분석 기사 • Nov 21
A Look At The Fair Value Of Core Laboratories Inc. (NYSE:CLB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$14.45 Core...내러티브 업데이트 • Sep 10
Middle East And Asia Pacific Markets Will Secure Energy Success
With both the discount rate and future P/E ratio remaining essentially stable, the consensus analyst price target for Core Laboratories was unchanged at $14.00. What's in the News Core Laboratories issued third quarter 2025 guidance, expecting revenue of $127.5–134.5 million, operating income of $13.6–16.2 million, operating margin of approximately 11%, and EPS of $0.18–0.22.분석 기사 • Sep 10
Core Laboratories Inc.'s (NYSE:CLB) 25% Jump Shows Its Popularity With Investors
Core Laboratories Inc. ( NYSE:CLB ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Jul 24
We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Jul 03
Core Laboratories (NYSE:CLB) Will Be Hoping To Turn Its Returns On Capital Around
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...분석 기사 • Jun 12
Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?
Key Insights The projected fair value for Core Laboratories is US$23.89 based on 2 Stage Free Cash Flow to Equity Core...분석 기사 • Apr 04
Core Laboratories Inc.'s (NYSE:CLB) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20x Core Laboratories Inc. ( NYSE:CLB ) may be sending bearish signals at...분석 기사 • Jan 21
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 27% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$27.00 Core...분석 기사 • Jan 03
Core Laboratories Inc. (NYSE:CLB) Not Lagging Market On Growth Or Pricing
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...분석 기사 • Dec 09
Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...분석 기사 • Nov 12
Is Core Laboratories (NYSE:CLB) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
새로운 내러티브 • Sep 24
New Product Launches And Deleveraging To Propel Growth Amidst Geopolitical Challenges
Diversification in geographical markets and services strengthens revenue by expanding market presence and targeting regions with growing demand.분석 기사 • Sep 19
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?
Key Insights The projected fair value for Core Laboratories is US$29.58 based on 2 Stage Free Cash Flow to Equity...분석 기사 • Aug 14
What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...분석 기사 • Jul 15
We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Jun 25
These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...분석 기사 • May 02
It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year
Key Insights Core Laboratories' Annual General Meeting to take place on 8th of May Salary of US$886.9k is part of CEO...분석 기사 • Mar 26
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?
Key Insights The projected fair value for Core Laboratories is US$22.93 based on 2 Stage Free Cash Flow to Equity Core...분석 기사 • Mar 02
Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price
Core Laboratories Inc.'s ( NYSE:CLB ) price-to-earnings (or "P/E") ratio of 19.8x might make it look like a sell right...매출 및 비용 세부 내역
매출 및 비용 세부 내역
Core Laboratories가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 525 | 29 | 45 | 0 |
| 31 Dec 25 | 527 | 30 | 44 | 0 |
| 30 Sep 25 | 518 | 32 | 43 | 0 |
| 30 Jun 25 | 517 | 30 | 41 | 0 |
| 31 Mar 25 | 518 | 28 | 40 | 0 |
| 31 Dec 24 | 524 | 31 | 39 | 0 |
| 30 Sep 24 | 523 | 26 | 38 | 0 |
| 30 Jun 24 | 514 | 24 | 39 | 0 |
| 31 Mar 24 | 511 | 38 | 34 | 0 |
| 31 Dec 23 | 510 | 37 | 39 | 0 |
| 30 Sep 23 | 509 | 41 | 39 | 0 |
| 30 Jun 23 | 510 | 39 | 40 | 0 |
| 31 Mar 23 | 503 | 24 | 41 | 0 |
| 31 Dec 22 | 490 | 19 | 38 | 0 |
| 30 Sep 22 | 487 | 15 | 40 | 0 |
| 30 Jun 22 | 479 | 9 | 45 | 0 |
| 31 Mar 22 | 477 | 10 | 48 | 0 |
| 31 Dec 21 | 470 | 20 | 44 | 0 |
| 30 Sep 21 | 459 | 31 | 28 | 0 |
| 30 Jun 21 | 446 | 33 | 22 | 0 |
| 31 Mar 21 | 443 | 19 | 21 | 0 |
| 31 Dec 20 | 487 | -97 | 33 | 0 |
| 30 Sep 20 | 530 | -101 | 47 | 0 |
| 30 Jun 20 | 598 | -80 | 50 | 0 |
| 31 Mar 20 | 651 | -55 | 50 | 0 |
| 31 Dec 19 | 668 | 94 | 47 | 0 |
| 30 Sep 19 | 685 | 92 | 63 | 0 |
| 30 Jun 19 | 694 | 90 | 65 | 0 |
| 31 Mar 19 | 700 | 96 | 68 | 0 |
| 31 Dec 18 | 701 | 80 | 63 | 0 |
| 30 Sep 18 | 698 | 93 | 50 | 0 |
| 30 Jun 18 | 678 | 91 | 48 | 0 |
| 31 Mar 18 | 661 | 87 | 47 | 0 |
| 31 Dec 17 | 648 | 81 | 48 | 0 |
| 30 Sep 17 | 627 | 75 | 45 | 0 |
| 30 Jun 17 | 608 | 71 | 41 | 0 |
| 31 Mar 17 | 598 | 67 | 41 | 0 |
| 31 Dec 16 | 590 | 65 | 39 | 0 |
| 30 Sep 16 | 628 | 64 | 43 | 0 |
| 30 Jun 16 | 682 | 81 | 47 | 0 |
| 31 Mar 16 | 738 | 99 | 48 | 0 |
| 31 Dec 15 | 798 | 115 | 50 | 0 |
| 30 Sep 15 | 893 | 166 | 49 | 0 |
| 30 Jun 15 | 972 | 199 | 49 | 0 |
양질의 수익: CLB는 $9.5M 규모의 큰 일회성 이익이 있어 31st March, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.
이익 마진 증가: CLB의 현재 순 이익률 (5.5%)은 지난해 (5.4%)보다 높습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: CLB의 수익은 지난 5년 동안 연평균 8.7% 증가했습니다.
성장 가속화: 지난 1년간 CLB 의 수익 증가율(3.6%)은 5년 평균(연간 8.7%)보다 낮습니다.
수익 대 산업: CLB의 지난 1년 수익 증가율(3.6%)은 Energy Services 업계의 -26.2%를 상회했습니다.
자기자본이익률
높은 ROE: CLB의 자본 수익률(10.7%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 12:54 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Core Laboratories Inc.는 30명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| James West | Barclays |
| Nicholas Green | Bernstein |
| Saurabh Pant | BofA Global Research |